NCT06914297View on ClinicalTrials.gov

TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 21, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

April 1, 2029

Conditions
Endometrial Cancer
Interventions
DRUG

TQB2450 injection + oral progestin

TQB2450 (1200 mg q3w ivgtt) + megestrol acetate (MA, 160 mg qd po)/megestrol acetate (MPA, 500 mg qd po)

Trial Locations (1)

200072

RECRUITING

Tenth People's Hospital of Tongji University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER